The global radiotherapy market is evaluated at US$8.058 billion for the year 2019 growing at a CAGR of 8.06% reaching the market size of US$13.861 billion by the year 2026.
The global radiotherapy market growth is expected to be driven by the reduction in treatment cost, the increase in cancer cases, large-scale investments in R&D for cancer treatments, and the development of non-invasive procedures for treatment. The factors such as availability of alternative therapy, inability to be used for metastasis state of cancer, and side effects like skin rashes are likely to hinder the global radiotherapy market.
A key factor expected to be responsible for market growth is the rise in the number of cancer cases at a global level. Cancer is one of the major life-threatening diseases of our times. According to the World Health Organization, cancer is the second leading cause of death, globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about one in six deaths are due to cancer. Approximately 70% of deaths from cancer occur in low and middle-income countries. Head and neck cancer account for nearly 5-6% of the cancer cases in the United States. It is the 15th most prevalent type of cancer in Europe, with nearly 56,000 cases diagnosed annually.
However, inadequate resources to meet the demands of radiotherapy and a lack of skilled, experienced professionals, to carry out the workload, are observed across all the major markets. The actual number of skilled personnel required to perform a radiotherapy procedure depends not only on the number of patients treated but also on other factors, such as the complexity of the treatment and the nature of the local equipment.
The demand for radiotherapy treatment increased in the United States over the years with a significant rise in the number of cancer cases. According to a report by the Centers for Disease Control & Prevention, the number of cancer cases increased from 15,74,811 in 2010 to 17,08,921 in 2018.
The advent of COVID-19 had an adverse impact on the global radiotherapy market.
The immense downturn in the global radiation oncology sites is due to the widespread scare of the pandemic during the year 2020. This restricted their movements and patients preferred to stay at home to reduce exposure. Even though the radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO). All 222 physician leaders in the survey, which was in the field April 16-30, said their practices continued to provide radiation therapy services during the early weeks of the pandemic, yet 85% also reported declines in the number of patients seen, by an average of one-third. Similarly, according to research by the University of Leeds, with Public Health England and the Royal College of Radiologists, reveals that there was a decrease in radiotherapy treatment courses of 19.9% in April, 6.2% in May, and 11.6% in June 2020, compared with the same months the previous year in England. The study also highlighted that the greater use of hypofractionated dosing regimens has helped radiation oncology sites deliver radiation therapy to cancer patients in England during the COVID-19 pandemic, offsetting a massive decline in treatment sessions overall. With the world recovering from the pandemic, many patients are expected to resume their treatments starting from the second quarter of 2021. This trend is expected to continue during the forecast period as well.
Asia Pacific region is expected to grow at a significant pace during the forecast period.
The rise in the demand for radiotherapy treatment in the region is major because of the exponential rise in the number of cancer cases in the region. According to a report published by the Cancer Atlas, in 2018, 8.2 million new cancer cases and 5.2 million cancer deaths were estimated in the region, corresponding to around half of the cancer burden worldwide. China alone accounted for 52% of new cancer cases (4.3 million) and 55% of cancer deaths (2.9 million) in the region. Overall, cancers of the lung (1,166,200 new cases, 15% of all cases), colorectum (914,200, 11%) and female breast (845,400, 10%) are the most common cancers. Lung cancer remains the leading cause of death (1,013,100 deaths, 21% of all deaths), followed by stomach (560,500, 11%) and liver cancer (554,000, 11%). Moreover, the region contributes to more than half of all cancer cases worldwide. This indicates the increasing adoption of radiotherapy measures in order to curb the disease in the coming years.
The global radiotherapy market growth is expected to be driven by the reduction in treatment cost, the increase in cancer cases, large-scale investments in R&D for cancer treatments, and the development of non-invasive procedures for treatment. The factors such as availability of alternative therapy, inability to be used for metastasis state of cancer, and side effects like skin rashes are likely to hinder the global radiotherapy market.
A key factor expected to be responsible for market growth is the rise in the number of cancer cases at a global level. Cancer is one of the major life-threatening diseases of our times. According to the World Health Organization, cancer is the second leading cause of death, globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about one in six deaths are due to cancer. Approximately 70% of deaths from cancer occur in low and middle-income countries. Head and neck cancer account for nearly 5-6% of the cancer cases in the United States. It is the 15th most prevalent type of cancer in Europe, with nearly 56,000 cases diagnosed annually.
However, inadequate resources to meet the demands of radiotherapy and a lack of skilled, experienced professionals, to carry out the workload, are observed across all the major markets. The actual number of skilled personnel required to perform a radiotherapy procedure depends not only on the number of patients treated but also on other factors, such as the complexity of the treatment and the nature of the local equipment.
The demand for radiotherapy treatment increased in the United States over the years with a significant rise in the number of cancer cases. According to a report by the Centers for Disease Control & Prevention, the number of cancer cases increased from 15,74,811 in 2010 to 17,08,921 in 2018.
The advent of COVID-19 had an adverse impact on the global radiotherapy market.
The immense downturn in the global radiation oncology sites is due to the widespread scare of the pandemic during the year 2020. This restricted their movements and patients preferred to stay at home to reduce exposure. Even though the radiation oncology clinics quickly implemented safety and process enhancements that allowed them to continue caring for cancer patients, according to a new national survey from the American Society for Radiation Oncology (ASTRO). All 222 physician leaders in the survey, which was in the field April 16-30, said their practices continued to provide radiation therapy services during the early weeks of the pandemic, yet 85% also reported declines in the number of patients seen, by an average of one-third. Similarly, according to research by the University of Leeds, with Public Health England and the Royal College of Radiologists, reveals that there was a decrease in radiotherapy treatment courses of 19.9% in April, 6.2% in May, and 11.6% in June 2020, compared with the same months the previous year in England. The study also highlighted that the greater use of hypofractionated dosing regimens has helped radiation oncology sites deliver radiation therapy to cancer patients in England during the COVID-19 pandemic, offsetting a massive decline in treatment sessions overall. With the world recovering from the pandemic, many patients are expected to resume their treatments starting from the second quarter of 2021. This trend is expected to continue during the forecast period as well.
Asia Pacific region is expected to grow at a significant pace during the forecast period.
The rise in the demand for radiotherapy treatment in the region is major because of the exponential rise in the number of cancer cases in the region. According to a report published by the Cancer Atlas, in 2018, 8.2 million new cancer cases and 5.2 million cancer deaths were estimated in the region, corresponding to around half of the cancer burden worldwide. China alone accounted for 52% of new cancer cases (4.3 million) and 55% of cancer deaths (2.9 million) in the region. Overall, cancers of the lung (1,166,200 new cases, 15% of all cases), colorectum (914,200, 11%) and female breast (845,400, 10%) are the most common cancers. Lung cancer remains the leading cause of death (1,013,100 deaths, 21% of all deaths), followed by stomach (560,500, 11%) and liver cancer (554,000, 11%). Moreover, the region contributes to more than half of all cancer cases worldwide. This indicates the increasing adoption of radiotherapy measures in order to curb the disease in the coming years.
Market Segmentation:
By Therapy type
- External Beam Radiotherapy
- Internal Beam Radiotherapy/Brachytherapy
- Systemic Radiotherapy
By Application
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Head And Neck Cancer
- Others
By End user
- Hospitals
- Ambulatory Surgical Centres
- Others
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- UK
- Others
- Middle East & Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- India
- Japan
- South Korea
- Taiwan
- Thailand
- Indonesia
- Others
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Radiotherapy Market Analysis, by Therapy type
6. Radiotherapy Market Analysis, by Application
7. Radiotherapy Market Analysis, by End-user
8. Radiotherapy Market Analysis, by Geography
9. Competitive Environment and Analysis
10. Company Profiles
Companies Mentioned
- Elekta AB
- Accuray Incorporated
- Ion Beam Applications (IBA)
- Isoray Medical, Inc.
- Canon Medical Systems Corporation
- Mirada Medical
- Eckert & Ziegler
- Siemens Healthineers
- Varian Medical Systems, Inc
- Mevion Medical Systems, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | July 2021 |
| Forecast Period | 2019 - 2026 |
| Estimated Market Value ( USD | $ 8.06 billion |
| Forecasted Market Value ( USD | $ 13.86 billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
